WILMINGTON, Del., Feb. 16, 2018 /PRNewswire/ -- AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved IMFINZI® (durvalumab) for the treatment of patients with unresectable Stage III...